Clinical Trials Logo

Clinical Trial Summary

This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03547297
Study type Observational
Source Alnylam Pharmaceuticals
Contact
Status Terminated
Phase
Start date May 29, 2018
Completion date January 15, 2019

See also
  Status Clinical Trial Phase
Completed NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Phase 3
Not yet recruiting NCT04923516 - Prevalence of Acute Hepatic Porphyria
Recruiting NCT05344599 - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed NCT02240784 - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Recruiting NCT04883905 - ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Approved for marketing NCT04056481 - Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria